Literature DB >> 32609843

Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion.

Shaimaa S Eissa1,2, Michael R Clay3, Teresa Santiago4, Gang Wu5, Lu Wang4, Barry L Shulkin6, Jennifer Picarsic7, Kim E Nichols2, Patrick K Campbell2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32609843      PMCID： PMC7362356          DOI： 10.1182/bloodadvances.2020001890

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  31 in total

Review 1.  Juvenile xanthogranulomas of the nervous system: A report of two cases and review of the literature.

Authors:  Jeremy K Deisch; Rajankumar Patel; Korgun Koral; Sandy D Cope-Yokoyama
Journal:  Neuropathology       Date:  2012-05-29       Impact factor: 1.906

Review 2.  Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.

Authors:  Carl E Allen; D Williams Parsons
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

3.  Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition.

Authors:  Olive S Eckstein; Johannes Visser; Carlos Rodriguez-Galindo; Carl E Allen
Journal:  Blood       Date:  2019-02-04       Impact factor: 22.113

4.  Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).

Authors:  Fleur Cohen Aubart; Jean-François Emile; Fabrice Carrat; Frédéric Charlotte; Neila Benameur; Jean Donadieu; Philippe Maksud; Ahmed Idbaih; Stéphane Barete; Khê Hoang-Xuan; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2017-06-30       Impact factor: 22.113

5.  BRAF V600E mutation detected in a case of Rosai-Dorfman disease.

Authors:  Giancarlo Fatobene; Julien Haroche; Zofia Hélias-Rodzwicz; Frédéric Charlotte; Valérie Taly; Aliana Meneses Ferreira; André Néder Ramires Abdo; Vanderson Rocha; Jean-François Emile
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

6.  Systemic juvenile xanthogranuloma with fatal outcome.

Authors:  Daniel Azorín; Antonio Torrelo; Alvaro Lassaletta; Inmaculada de Prada; Isabel Colmenero; Trinidad Contra; Imelda González-Mediero
Journal:  Pediatr Dermatol       Date:  2009 Nov-Dec       Impact factor: 1.588

7.  Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.

Authors:  Julien Haroche; Oussama Abla
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

8.  Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.

Authors:  Benjamin H Durham; Estibaliz Lopez Rodrigo; Jennifer Picarsic; David Abramson; Veronica Rotemberg; Steven De Munck; Erwin Pannecoucke; Sydney X Lu; Alessandro Pastore; Akihide Yoshimi; Diana Mandelker; Ozge Ceyhan-Birsoy; Gary A Ulaner; Michael Walsh; Mariko Yabe; Kseniya Petrova-Drus; Maria E Arcila; Marc Ladanyi; David B Solit; Michael F Berger; David M Hyman; Mario E Lacouture; Caroline Erickson; Ruth Saganty; Michelle Ki; Ira J Dunkel; Vicente Santa-María López; Jaume Mora; Julien Haroche; Jean-Francois Emile; Olivier Decaux; Frederic Geissmann; Savvas N Savvides; Alexander Drilon; Eli L Diamond; Omar Abdel-Wahab
Journal:  Nat Med       Date:  2019-11-25       Impact factor: 53.440

9.  Transforming growth factor β inhibits platelet derived growth factor-induced vascular smooth muscle cell proliferation via Akt-independent, Smad-mediated cyclin D1 downregulation.

Authors:  Abel Martin-Garrido; Holly C Williams; Minyoung Lee; Bonnie Seidel-Rogol; Xinpei Ci; Jin-Tang Dong; Bernard Lassègue; Alejandra San Martín; Kathy K Griendling
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

Review 10.  Gene Expression Profiling of Human Monocyte-derived Dendritic Cells - Searching for Molecular Regulators of Tolerogenicity.

Authors:  Katina Schinnerling; Paulina García-González; Juan Carlos Aguillón
Journal:  Front Immunol       Date:  2015-10-19       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.